|
|
||||||||||
|
J Am Coll Cardiol, 2004; 44:10-13, doi:10.1016/j.jacc.2004.04.016 © 2004 by the American College of Cardiology Foundation |
* University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Manuscript received September 5, 2003; accepted February 5, 2004.
* Reprint requests and correspondence: Dr. Bertram Pitt, 1500 East Medical Center Drive, 3214 Taubman Center, Ann Arbor, Michigan 48109, USA.
Bpitt{at}umich.edu
The introduction of generic drugs should lower health care costs by reducing the price of drugs. The realization of this goal may, however, not be fully achieved: generic drugs may be underused or misused in comparison to prescription drugs because of a lack of ongoing postgraduate physician education. More importantly, there is little incentive to explore new indications for soon-to-be generic drugs and drugs that are already generic. The failure to explore new indications for soon-to-be and existing generic drugs may result in a missed opportunity to further reduce health care costs. Thus, the apparent savings resulting from the introduction of generic drugs may not be fully realized unless the government and other third-party payers take a more active role in postgraduate drug education and investigation.
| ||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |